Vir Biotechnology
237 hedge funds and large institutions have $1.49B invested in Vir Biotechnology in 2026 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 93 increasing their positions, 76 reducing their positions, and 43 closing their positions.
119% more call options, than puts
Call options by funds: $4.11M | Put options by funds: $1.88M
22% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 76
20% more capital invested
Capital invested by funds: $1.25B → $1.49B (+$245M)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
6% less funds holding
Funds holding: 252 → 237 (-15)
13.08% less ownership
Funds ownership: 100% → 86.93% (-13%)
23% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$35.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$26.9M |
| 3 |
BlackRock
New York
|
+$25.5M |
| 4 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$21.7M |
| 5 |
SAI
Savvy Advisors Inc
New York
|
+$9.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$12.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$10.5M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$9.53M |
| 4 |
Goldman Sachs
New York
|
-$8.42M |
| 5 |
Morgan Stanley
New York
|
-$6.12M |
VIR Hedge Fund Activity: Q2 2026 in Review
237 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q2 2026, worth a combined $1.49B — up 20% from $1.25B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of VIR and 33 opened new positions — a net loss of 10 holders — while 76 trimmed existing stakes and 93 added.
The largest buyer was Point72 Asset Management, adding an estimated $35.3M. The largest seller was Jacobs Levy Equity Management, cutting an estimated $12.4M.
- 237 institutional investors held Vir Biotechnology (VIR) as of Q2 2026, down from 252 in Q1 2026.
- Funds reported $1.49B of Vir Biotechnology stock for Q2 2026, up 20% quarter-over-quarter.
- 33 funds opened new Vir Biotechnology positions in Q2 2026 and 43 closed out, a net change of -10 holders.
- The largest Vir Biotechnology buyer in Q2 2026 was Point72 Asset Management, an estimated $35.3M added.
- The largest Vir Biotechnology seller in Q2 2026 was Jacobs Levy Equity Management, an estimated $12.4M sold.
Based on aggregated 13F filings for Q2 2026.